One size rarely fits all. That's true for clothes, and it's true for coronavirus vaccine stocks. In this Motley Fool Live video recorded on Dec. 3, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss COVID vaccine stock ideas for different investing styles.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2020
Corinne Cardina: Last question. Any tips that you would give investors for investing in the coronavirus vaccine landscape? I ask you this every week. I just want to make sure that your advice hasn't changed given the new updates and developments that have happened.
Keith Speights: I am being steady-Eddy on this, Corinne.
If you are a conservative investor, risk-averse, go with a stock like a Johnson & Johnson (JNJ 0.82%). It's a Dividend Aristocrat, healthcare giant, been around for nearly forever.
Brian Orelli, who is a fellow Fool, has his Ph.D. in biology. Brian wrote a great article a few years ago that I still remember. He said, "Anytime is a great time to buy J&J if you hold on long enough." That is the kind of stock that a conservative investor would want to go with.
If you're more risk-tolerant, looking for more aggressive growth, a Moderna (MRNA 3.01%), perhaps. BioNTech (BNTX 1.38%), Novavax (NVAX 2.52%) is a possibility there.
If you're really aggressive, you could go with one of these earlier-stage companies like an Arcturus (ARCT 4.16%) or Vaxart (VXRT 0.91%), like we just mentioned.
If you're somewhere in the middle, I like Pfizer (PFE 1.00%). It is going to have a much better growth story going forward, and they also have a great dividend. Pfizer's kind of good middle-of-the-road pick.
